May 3, 2021
As a partner of Chiauranib/CS2164 project, BLA Regulatory congratulates Chipscreen on receiving US FDA IND approval
As a partner of Chiauranib/CS2164 project, BLA Regulatory congratulates Chipscreen on receiving US FDA IND approval Gaithersburg, MD (03 May 2021) – BLA Regulatory, LLC, a full-service biopharma regulatory consultancy, announced that as a partner of Chiauranib/CS2164 project, BLA Regulatory congratulates Shenzhen Chipscreen Biosciences on receiving Investigational New Drug (IND) clearance from the US Food […]
As a partner of Chiauranib/CS2164 project, BLA Regulatory congratulates Chipscreen on receiving US FDA IND approval
As a partner of Chiauranib/CS2164 project, BLA Regulatory congratulates Chipscreen on receiving US FDA IND approval Gaithersburg, MD (03 May...
As a partner of CD4B bi-antibody project, BLA Regulatory congratulates I-Mab on receiving US FDA IND approval
As a partner of CD4B bi-antibody project, BLA Regulatory congratulates I-Mab on receiving US FDA IND approval Gaithersburg, MD (03...
2020 End of the Year Summary Report-2 FDA Approved 13 New Large Molecule Drugs and 2 New Gene Therapy Products
2020 End of the Year Summary Report-2 FDA Approved 13 New Large Molecule Drugs and 2 New Gene Therapy Products...